Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Transcode Therapeutics, Inc.RNAZ · Entity 8499 | Director · Chief Executive Officer | September 28, 2023 | October 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Transcode Therapeutics, Inc.
Report date September 28, 2023 · Filed October 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,262 |
Reported balance
After 2023-09-28 transaction · row 1
1 source rowRow 1 · 2023-09-28 · Purchase · Acquired 98,000 · Balance 180,262 F1: Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2023 Filed Oct 2, 2023 16:37 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | PurchaseCommon Stock | 98,000 | $0.51 | $49,980.00 |
DisclosureSEC source: 0001104659-23-105924 · tm2327413-1_4seq1.xml · nonDerivative · entry 1 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,262 F1 · kind: Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 18:23 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | PurchaseCommon Stock | 12,000 | $2.65 | $31,818.00 |
DisclosureSEC source: 0001104659-23-073872 · tm2319496-1_4seq1.xml · nonDerivative · entry 2 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,262 F2 · price: Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 18:23 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | PurchaseCommon Stock | 6,607 | $2.55 | $16,846.53 |
DisclosureSEC source: 0001104659-23-073872 · tm2319496-1_4seq1.xml · nonDerivative · entry 1 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,262 F1 · price: Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 16:16 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | PurchaseCommon Stock | 19,000 | $2.76 | $52,440.00 |
DisclosureSEC source: 0001104659-23-070804 · tm2318573-1_4seq1.xml · nonDerivative · entry 1 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912,114 F1 · price: Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 16:16 UTC Amendment | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | PurchaseCommon Stock | 19,000 | $2.76 | $52,440.00 |
DisclosureSEC source: 0001104659-23-071204 · tm2318742-1_4aseq1.xml · nonDerivative · entry 1 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,155 F1 · price: Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price. F2 · balance_after: This Form 4/A amends the Form 4 originally filed on June 13, 2023 solely to correct the amount reported in Table I, Column 5. Due to an administrative error, the amount reported on the original Form 4 was not adjusted to reflect a 1-for-20 reverse stock split of the Company's common stock, which became effective as of May 22, 2023. Read SEC document |
| May 19, 2023 Filed May 19, 2023 20:06 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (right to buy) · Derivative | 735,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001104659-23-062813 · tm2316383-2_4seq1.xml · derivative · entry 1 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,000 Underlying: Common Stock · 735,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 20:11 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001104659-22-127084 · tm2232745-2_4seq1.xml · derivative · entry 1 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-12-11 F1 · derivative.exercise_date: Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (December 1, 2022). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 18:44 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | PurchaseCommon Stock | 20,000 | $1.15 | $23,000.00 |
DisclosureSEC source: 0001104659-22-100931 · tm2226100-1_4seq1.xml · nonDerivative · entry 1 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,114 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.12 to $1.1761, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 16:01 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | PurchaseCommon Stock | 2,000 | $1.87 | $3,739.80 |
DisclosureSEC source: 0001104659-22-067099 · tm2217388-1_4seq1.xml · nonDerivative · entry 2 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873,114 Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:01 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | PurchaseCommon Stock | 28,000 | $1.84 | $51,643.20 |
DisclosureSEC source: 0001104659-22-067099 · tm2217388-1_4seq1.xml · nonDerivative · entry 1 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871,114 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 06:03 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-22-011081 · tm225233-1_4seq1.xml · derivative · entry 1 Dudley Robert Michael · CIK 0001854161 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2031-01-31 F1 · derivative.exercise_date: Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.